open access

Vol 64, No 4 (2013)
Original paper
Submitted: 2013-09-03
Accepted: 2013-09-03
Published online: 2013-09-03
Get Citation

Immunohistochemical detection of follicle stimulating hormone receptor (FSHR) in neuroendocrine tumours

Marek Pawlikowski, Katarzyna Winczyk, Henryk Stępień
DOI: 10.5603/EP.2013.0004
·
Endokrynol Pol 2013;64(4):268-271.

open access

Vol 64, No 4 (2013)
Original Paper
Submitted: 2013-09-03
Accepted: 2013-09-03
Published online: 2013-09-03

Abstract

Introduction: Follicle stimulating hormone receptors (FSHR) are well known to be expressed in gonads and in gonadal tumours. Recently,their incidence has also been revealed in endocrine non-gonadal tumours such as adrenal and pituitary tumours. Moreover, FSHR immunostaininghas also been reported in endothelium of intra- and peritumoral blood vessels of a large series of cancers. The presentpaper reports on the incidence of FSHR in both tumoral cells and some intratumoral blood vessels of neuroendocrine tumours (NETs).

Material and methods: Sixteen NETs samples were taken from 14 patients. The tumour samples were immunostained using the antibodyraised against 1-190 amino acid sequence from the human FSH-R and anti-Ki67 antibody.

Results: In all the samples examined, the majority of tumoral cells were immunostained with anti-FSHR antibody. Positive immunostainingconcerned also the intratumoral blood vessels endothelia in a half of the examined samples. Immunopositive blood vessels were foundmore often in tumours with higher Ki-67 index.

Conclusion: FSHR expressed in NETs, if they are functional, may mediate the signals which can enhance further tumour growth.

Abstract

Introduction: Follicle stimulating hormone receptors (FSHR) are well known to be expressed in gonads and in gonadal tumours. Recently,their incidence has also been revealed in endocrine non-gonadal tumours such as adrenal and pituitary tumours. Moreover, FSHR immunostaininghas also been reported in endothelium of intra- and peritumoral blood vessels of a large series of cancers. The presentpaper reports on the incidence of FSHR in both tumoral cells and some intratumoral blood vessels of neuroendocrine tumours (NETs).

Material and methods: Sixteen NETs samples were taken from 14 patients. The tumour samples were immunostained using the antibodyraised against 1-190 amino acid sequence from the human FSH-R and anti-Ki67 antibody.

Results: In all the samples examined, the majority of tumoral cells were immunostained with anti-FSHR antibody. Positive immunostainingconcerned also the intratumoral blood vessels endothelia in a half of the examined samples. Immunopositive blood vessels were foundmore often in tumours with higher Ki-67 index.

Conclusion: FSHR expressed in NETs, if they are functional, may mediate the signals which can enhance further tumour growth.

Get Citation

Keywords

FSH receptors, neuroendocrine tumours, vascular endothelium

About this article
Title

Immunohistochemical detection of follicle stimulating hormone receptor (FSHR) in neuroendocrine tumours

Journal

Endokrynologia Polska

Issue

Vol 64, No 4 (2013)

Article type

Original paper

Pages

268-271

Published online

2013-09-03

Page views

1574

Article views/downloads

2280

DOI

10.5603/EP.2013.0004

Bibliographic record

Endokrynol Pol 2013;64(4):268-271.

Keywords

FSH receptors
neuroendocrine tumours
vascular endothelium

Authors

Marek Pawlikowski
Katarzyna Winczyk
Henryk Stępień

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl